1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,306 | 0,322 | 13:02 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.09. | Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry | 201 | PR Newswire | Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical... ► Artikel lesen | |
| 29.09. | Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry | 278 | PR Newswire | Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical... ► Artikel lesen | |
| 25.09. | VIVA BIOTECH (01873): INTERIM REPORT 2025 | - | HKEx | ||
| 02.09. | Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights | 219 | PR Newswire | SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge... ► Artikel lesen | |
| 28.08. | Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth | 310 | PR Newswire | Financial Highlights for Interim Results ended 30 June 2025Revenue reached RMB831.9 millionGross profit amounted to RMB339.4 millionGross profit margin was 40.8%, an increase of 6.3 percentage... ► Artikel lesen | |
| 28.08. | VIVA BIOTECH (01873): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 2 | HKEx | ||
| 18.08. | VIVA BIOTECH (01873): DATE OF BOARD MEETING | 2 | HKEx | ||
| VIVA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 12.06. | VIVA BIOTECH (01873): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 12, 2025 | 2 | HKEx | ||
| 04.06. | VIVA BIOTECH (01873): SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CONNECTED TRANSACTION | - | HKEx | ||
| 30.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 28.05. | VIVA BIOTECH (01873): CONNECTED TRANSACTION INVESTMENT IN LIMITED PARTNERSHIP FUND | 1 | HKEx | ||
| 15.05. | Viva Biotech Launches the AI-Driven Drug Discovery Platform, Transforming New Drug R&D Logic, Enabling One-Stop Innovative Drug Discovery | 332 | PR Newswire | SHANGHAI, May 15, 2025 /PRNewswire/ -- On May 13, 2025, Viva Biotech successfully held the AIDD platform launch event "Enchantment of Drug Discovery," unveiling the advanced and comprehensive... ► Artikel lesen | |
| 06.05. | VIVA BIOTECH (01873): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): PROPOSED RE-ELECTION OF RETIRING DIRECTORS PROPOSED RE-APPOINTMENT OF AUDITOR PROPOSALS FOR GRANTING OF GENERAL MANDATES TO ISSUE ... | - | HKEx | ||
| 24.04. | VIVA BIOTECH (01873): 2024 ANNUAL REPORT | - | HKEx | ||
| 28.03. | Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection | 360 | PR Newswire | SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings... ► Artikel lesen | |
| 27.03. | Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D | 166 | PR Newswire | Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 4,456 | -0,40 % | Valneva korrigiert Finanzziele - Hoffnung bleibt auf Lyme-Impfstoff ab 2027 | Valneva hat eine neue Kreditfazilität über bis zu 500 Millionen US-Dollar mit von Pharmakon Advisors verwalteten Fonds abgeschlossen. Eine erste Tranche von 215 Millionen US-Dollar dient zur vollständigen... ► Artikel lesen | |
| NOVONESIS | 52,84 | +0,11 % | Novonesis Hosts National Flagship Manufacturing Day Event at North America Headquarters | ||
| GENMAB | 272,30 | -0,37 % | Truist Securities raises Genmab stock price target to $49 on Merus acquisition | ||
| ARBUTUS BIOPHARMA | 3,560 | +0,45 % | Arbutus Biopharma Corp - 8-K, Current Report | ||
| BEONE MEDICINES LTD ADR | 284,00 | +2,90 % | BeOne Medicines price target raised to $362 from $259 at Bernstein | ||
| SINO BIOPHARM | 0,790 | +1,28 % | Aktienmarkt: Aktie von Sino Biopharmaceutical tritt auf der Stelle (0,88 €) | Wenig Kursbewegung zur Stunde bei der Sino Biopharmaceutical-Aktie . Das Wertpapier notiert aktuell bei 0,88 Euro. Ein geringes Minus von 5,12 Prozent zeigt die Kurstafel für die Aktie von Sino Biopharmaceutical... ► Artikel lesen | |
| VERICEL | 29,200 | +5,80 % | Vericel Corporation: Vericel Reports Second Quarter 2025 Financial Results | Total Revenue Growth of 20% to $63.2 Million, with MACI Revenue Growth of 21% to $53.5 Million Gross Margin Increased More than 400 Basis Points to 74% Adjusted EBITDA Growth of 112% to $13.4 Million... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,510 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia | Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech,... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 11,260 | -2,85 % | Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | - Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
| MUSTGROW BIOLOGICS | 0,403 | +1,51 % | MustGrow Biologics Corp.: MustGrow Announces Grant of RSUs and DSUs | Saskatoon, Saskatchewan--(Newsfile Corp. - September 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow") today announced that the board of directors... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 2,250 | +3,45 % | BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements | NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in... ► Artikel lesen | |
| ZAI LAB LTD ADR | 26,600 | +1,53 % | Zai Lab Limited: Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 | -Data highlights potential of ZL-1503 as a promising treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Favorable preclinical safety profile, prolonged... ► Artikel lesen | |
| REGENXBIO | 9,600 | +2,13 % | The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts | ||
| CSTONE PHARMACEUTICALS | 0,760 | +3,40 % | CSTONE PHARMA-B (02616): INTERIM REPORT 2025 | ||
| AKEBIA | 2,400 | +1,18 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen |
Das Unternehmen VIVA BIOTECH HOLDINGS kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -8,98 % bei einem Aktienkurs von 0,304 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVA BIOTECH HOLDINGS finden Sie auf Wallstreet Online.